Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Phthiobuzonum/diclothane compound topical formulation

A topical technology of phthalide, which is applied in the compound topical preparation of phthalide/dyclonine and its preparation to treat herpes simplex and herpes zoster skin diseases, so as to shorten the course of the disease, relieve the pressure of patients, The effect of improving the quality of life

Active Publication Date: 2009-01-14
BEIJING HUMANWELL JUNWEI PHARM TECH CO LTD
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] At present, there is no report on the combination of phthalide and dyclonine and its use in the treatment of viral skin diseases such as herpes zoster

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Phthiobuzonum/diclothane compound topical formulation
  • Phthiobuzonum/diclothane compound topical formulation
  • Phthiobuzonum/diclothane compound topical formulation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1 Phthaloin / dyclonine ointment

[0041] Phthalate 2g

[0042] Dyclonine 1g

[0043] Dimethylformamide 5ml

[0044] Cetyl Alcohol 3g

[0045] Stearyl alcohol 3g,

[0046] Sodium Lauryl Sulfate 0.5g

[0047] Glycerol monostearate 7g

[0048] Distilled water 68ml

[0049] Glycerin 10ml

[0050] Preparation method: heat cetyl alcohol, stearyl alcohol, and glycerol monostearate, keep warm at 90 degrees, and heat sodium lauryl sulfate, glycerin, and water, and stir and mix with the above liquid to make a matrix, and then take The raw materials of phthalocyanine and dyclonine are dissolved in dimethylformamide, added to the prepared matrix, stirred and mixed well.

Embodiment 2

[0051] Example 2 Phthaloin / dyclonine gel

[0052] Phthalate 2g

[0053] Dyclonine 1g

[0054] Sodium Carboxymethyl Cellulose 3g

[0055] Propylene Glycol 10g

[0056] Dimethylformamide amount

[0057] Ethyl Nibelgin 0.1g

[0058] Add distilled water to 100g

[0059] Preparation method: Soak sodium carboxymethyl cellulose in 60ml of water for 24 hours for later use, and dissolve phthalocyanine and dyclonine with an appropriate amount of dimethylformamide, add them to sodium carboxymethyl cellulose soaked in water, Add propylene glycol, ethyl paraben and distilled water to the full amount and stir well.

Embodiment 3

[0060] Example 3 Phthaloin / dyclonine liniment

[0061] Phthalate 0.5g

[0062] Dyclonine 1g

[0063] Propylene Glycol 20ml

[0064] Azone 1ml

[0065] Triacetin add to 100ml

[0066] Preparation method: Mix the above-mentioned phthalodin, dyclonine, propylene glycol, azone, and an appropriate amount of triacetin, heat to dissolve, add triacetin to the full amount, and stir and mix well.

[0067] Similarly, the following examples are all expressed in terms of active ingredients and active ingredient ratios, and specific dosage forms and corresponding inactive ingredients refer to Example 1, or 2, or 3.

[0068]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound topical preparation of fitbamzone dyclonine used for curing viral skin diseases, such as herpes zoster, etc. The topical preparation of fitbamzone dyclonine complex prescription consists of following components by percentage composition: (1) 0.1 to 10 weight percent of the fitbamzone, (2) 0.1 to 10 weight percent of the dyclonine, and (3) pharmaceutically acceptable excipient. The compound topical preparation used for curing the herpes zoster can stop pain, immediately relieve the suffering of a patient to the maximum, improve the life quality of the patient and contribute to improve the clinical compliance of the patient based on ensuring the curative effect of anti-virus and achieving the purpose of treatment. The compound topical preparation has the advantages of having an evident curative effect on the herpes zoster, a good analgesic effect, stable preparation performance, controllable quality, a good curative effect, and nonirritant to skin without causing allergic reaction.

Description

technical field [0001] The present invention relates to topical pharmaceutical preparations, more particularly, to a compound topical preparation of phthalodin / dyclonine and a preparation method thereof, which are used for the treatment of herpes simplex and herpes zoster skin diseases. Background technique [0002] Viral infection has always been a serious social topic that people are concerned about. Viral infection causes a variety of diseases and seriously threatens people's health. Viral skin diseases occupy an important position in skin diseases, among which Herpes Zoster is caused by chickenpox. Acute inflammatory skin disease caused by the herpes zoster virus, Chinese medicine is called "Long Yao Huo Long", "Lang Yao Huo Dan", commonly known as "spider sore". Its main feature is clustered blisters, distributed in clusters along one peripheral nerve, accompanied by obvious neuralgia. The initial infection is chickenpox. Afterwards, the virus can be latent in the dors...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/472A61K31/435A61K9/06A61K9/107A61K9/00A61P31/12A61P17/00
Inventor 高永良李志红王晋李劲彤
Owner BEIJING HUMANWELL JUNWEI PHARM TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products